BriaCell presents at 2024 SITC Annual Meeting in Philadelphia

BriaCell Therapeutics Corp., a clinical-stage biotechnology company, announced its participation in the Society for Immunotherapy of Cancer's 39th Annual Meeting, scheduled for November 6-10, 2024, in Houston, Texas. The company will present a poster detailing its research on novel immunotherapy candidates aimed at improving treatment for breast and prostate cancer patients. Miguel Lopez-Lago, PhD, the Chief Scientific Officer, expressed enthusiasm about sharing their findings at this prestigious event, highlighting the company's commitment to advancing cancer care. The presentation will take place on November 8, 2024, from 9:00 am to 7:00 pm CST at the George R. Brown Convention Center. Following the event, the poster will be made available on BriaCell's website, allowing broader access to their research findings. This opportunity underscores BriaCell's ongoing efforts to contribute to the field of immunotherapy and its potential impact on patient outcomes. BriaCell's focus on targeted immunotherapy candidates reflects a strategic approach to addressing the complexities of cancer treatment. The company aims to leverage its research to develop therapies that can significantly improve the quality of life for patients battling these challenging diseases. As the company continues its clinical studies, it remains committed to transparency and sharing its progress with the scientific community. The announcement also includes a cautionary note regarding forward-looking statements, emphasizing the inherent risks and uncertainties associated with clinical research. BriaCell's management encourages stakeholders to review their filings for a comprehensive understanding of the potential challenges ahead as they pursue innovative cancer therapies.